Biohaven Ltd. (BHVN) Price & Analysis

Compare

834 Followers

BHVN Stock Chart & Stats

$11.83

-$0.59(-1.49%)

At close: Jan 08 4:00 PM EST

$11.83

-$0.59(-1.49%)

Day’s Range― - ―

52-Week Range$7.48 - $44.28

Previous CloseN/A

Volume146.24K

Average Volume (3M)2.86M

Market Cap

$1.72B

Enterprise Value$1.38B

Total Cash (Recent Filing)$260.22M

Total Debt (Recent Filing)$314.18M

Price to Earnings (P/E)―

Beta1.45

Next Earnings

Mar 19, 2026

EPS Estimate

-1.19

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.64

Shares Outstanding145,188,490

10 Day Avg. Volume2,018,006

30 Day Avg. Volume2,864,151

Financial Highlights & Ratios

PEG Ratio-0.06

Price to Book (P/B)8.05

Price to Sales (P/S)0.00

P/FCF Ratio-5.81

Enterprise Value/Market Cap0.80

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-1.25K

Enterprise Value/Ebitda-1.75

Forecast

1Y Price Target

$16.73

Price Target Upside41.42% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering14

EPS Forecast (FY)-3.13

Revenue Forecast (FY)$4.84M

Bulls Say, Bears Say

Bulls Say

Clinical Trial CatalystBHV-7000 has shown a clean safety profile in prior testing and focused development toward an epilepsy pivotal readout could validate the program and drive investor interest.

Immunology Program AdvancementAn immune-targeted degrader program produced substantial reductions in disease-related antibodies and is being advanced into an expanded trial with plans toward a pivotal study.

Portfolio Focus And Cost OptimizationPortfolio reprioritization and R&D cost optimization concentrate resources on a smaller number of late-stage programs with higher commercial potential, increasing the likelihood of meaningful milestones.

Bears Say

Clinical Efficacy UncertaintyA proof-of-concept study for the potassium-channel activator failed to meet its primary endpoint in major depressive disorder and persistent questions about adequate brain exposure undermine confidence in the program's prospects.

Financial Runway And Pipeline OptionalityAvailable cash is limited relative to historical spending, prompting aggressive R&D cuts and delays to lower-priority trials that reduce pipeline optionality and raise the risk of missing value-creating data.

Regulatory SetbackA complete response letter for Vyglxia criticized the use of real-world data as a comparator, leaving the drug's approval pathway uncertain and removed from near-term valuation models.

Biohaven Ltd. News

Midday Fly By: Netflix reports Q4 beat, Smithfield to acquire Nathan’s

The major averages were broadly higher at noon in a bounce-back from yesterday’s sharp selloff, though sentiment remains...

13d ago

ANF

Biohaven upgraded to Outperform from Sector Perform at RBC Capital

RBC Capital upgraded Biohaven (BHVN) to Outperform from Sector Perform with a price target of $22, up from...

14d ago

BHVN

Biohaven price target raised to $15 from $10 at BofA

BofA raised the firm’s price target on Biohaven (BHVN) to $15 from $10 and keeps a Neutral rating...

22d ago

BHVN

Biohaven reports ‘positive’ early experience from Priority Degrader Programs

Biohaven (BHVN) highlighted its “broad portfolio progress” at the 44th Annual J.P. Morgan Healthcare Conference, the company reported....

22d ago

BHVN

Biohaven highlights degrader platforms in new investor presentation

The latest announcement is out from Biohaven Ltd. ( ($BHVN) ). On January 12, 2026, Biohaven Ltd. announced...

22d ago

BHVN

Biohaven Announces $125 Million Targeted Equity Financing

The latest update is out from Biohaven Ltd. ( ($BHVN) ). On January 6, 2026, Biohaven Ltd. agreed...

28d ago

BHVN

Biohaven: MDD Setback but Epilepsy Refocus and Diversified Pipeline Support Continued Buy Rating

Leerink Partners analyst Marc Goodman has maintained their bullish stance on BHVN stock, giving a Buy rating on...

1M ago

BHVN

Biohaven: Core Pipeline Strength and Upcoming Clinical Catalysts Support Buy/High Risk Rating Despite BHV-7000 MDD Setback

Citi analyst Samantha Semenkow has maintained their bullish stance on BHVN stock, giving a Buy rating yesterday. Samantha...

1M ago

BHVN

Biohaven reports BHV-7000 trial misses primary endpoint

Biohaven (BHVN) reported results from a Phase 2 proof-of-concept study evaluating BHV-7000 for the treatment of major depressive...

1M ago

BHVN

Biohaven presents data for BHV-1510 at ESMO

Biohaven (BHVN) announced that it presented clinical safety and efficacy data for BHV-1510 at the 2025 European Society...

2M ago

BHVN

Biohaven downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Biohaven (BHVN) to Neutral from Buy with a price target of $11, down from $30....

2M ago

BHVN

Midday Fly By: Dell, HP move in opposite directions after earnings

Stocks are higher near noon as traders lean into the idea that the Federal Reserve is ready to...

2M ago

Autodesk upgraded, Nio downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

2M ago

Biohaven downgraded to Neutral from Buy at UBS

UBS downgraded Biohaven (BHVN) to Neutral from Buy with a price target of $11, down from $26. The...

2M ago

BHVN

BHVN FAQ

What was Biohaven Ltd.’s price range in the past 12 months?

Biohaven Ltd. lowest stock price was $7.48 and its highest was $44.28 in the past 12 months.

What is Biohaven Ltd.’s market cap?

Biohaven Ltd.’s market cap is $1.72B.

When is Biohaven Ltd.’s upcoming earnings report date?

Biohaven Ltd.’s upcoming earnings report date is Mar 19, 2026 which is in 43 days.

How were Biohaven Ltd.’s earnings last quarter?

Biohaven Ltd. released its earnings results on Nov 10, 2025. The company reported -$1.64 earnings per share for the quarter, beating the consensus estimate of -$1.901 by $0.261.

Is Biohaven Ltd. overvalued?

According to Wall Street analysts Biohaven Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Biohaven Ltd. pay dividends?

Biohaven Ltd. does not currently pay dividends.

What is Biohaven Ltd.’s EPS estimate?

Biohaven Ltd.’s EPS estimate is -1.19.

How many shares outstanding does Biohaven Ltd. have?

Biohaven Ltd. has 145,188,490 shares outstanding.

What happened to Biohaven Ltd.’s price movement after its last earnings report?

Biohaven Ltd. reported an EPS of -$1.64 in its last earnings report, beating expectations of -$1.901. Following the earnings report the stock price went down -5.69%.

Which hedge fund is a major shareholder of Biohaven Ltd.?

Currently, no hedge funds are holding shares in BHVN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Biohaven Ltd. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-522.08%

Trailing 12-Months

Asset Growth

-19.86%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Biohaven Ltd.

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.

Biohaven Ltd. (BHVN) Earnings & Revenues

Historic Earnings Reports

BHVN Stock 12 Month Forecast

Average Price Target

$16.73

▲(41.42% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","39":"$39","15.75":"$15.75","23.5":"$23.5","31.25":"$31.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.73,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,15.75,23.5,31.25,39],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.29,12.72923076923077,14.168461538461537,15.607692307692307,17.046923076923076,18.486153846153847,19.925384615384615,21.364615384615384,22.803846153846152,24.243076923076924,25.682307692307692,27.121538461538464,28.560769230769232,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.29,11.708461538461538,12.126923076923076,12.545384615384615,12.963846153846154,13.382307692307691,13.80076923076923,14.21923076923077,14.637692307692308,15.056153846153846,15.474615384615385,15.893076923076922,16.31153846153846,{"y":16.73,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.29,11.113846153846152,10.937692307692307,10.76153846153846,10.585384615384616,10.409230769230769,10.233076923076922,10.056923076923077,9.88076923076923,9.704615384615384,9.528461538461539,9.352307692307692,9.176153846153847,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":37.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.25,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.68,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.96,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.71,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.89,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.82,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.32,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.29,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >